|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001206,
umls-concept:C0001758,
umls-concept:C0078058,
umls-concept:C0172537,
umls-concept:C0175630,
umls-concept:C0301630,
umls-concept:C0441889,
umls-concept:C0681850,
umls-concept:C0913469,
umls-concept:C1171892,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C2349001,
umls-concept:C2697811
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2006-11-7
|
|
pubmed:abstractText |
Vascular endothelial growth factor (VEGF) is involved in activation of the matrix metalloproteinase (MMP) system; the latter is implicated in atherosclerosis and cardiovascular disease. Patients with acromegaly have reduced life expectancy primarily due to cardiac disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0021-972X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4635-40
|
|
pubmed:meshHeading |
pubmed-meshheading:16926249-Acromegaly,
pubmed-meshheading:16926249-Adult,
pubmed-meshheading:16926249-Aged,
pubmed-meshheading:16926249-Body Mass Index,
pubmed-meshheading:16926249-Female,
pubmed-meshheading:16926249-Human Growth Hormone,
pubmed-meshheading:16926249-Humans,
pubmed-meshheading:16926249-Insulin-Like Growth Factor I,
pubmed-meshheading:16926249-Male,
pubmed-meshheading:16926249-Matrix Metalloproteinase 2,
pubmed-meshheading:16926249-Middle Aged,
pubmed-meshheading:16926249-Vascular Endothelial Growth Factor A
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly.
|
|
pubmed:affiliation |
Department of Endocriniology, Christie Hospital, Manchester, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|
